<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">HIV Clin Trials</journal-id><journal-id journal-id-type="iso-abbrev">HIV Clin Trials</journal-id><journal-id journal-id-type="archive">YHCT</journal-id><journal-id journal-id-type="publisher-id">yhct20</journal-id><journal-title-group><journal-title>HIV Clinical Trials</journal-title></journal-title-group><issn pub-type="ppub">1528-4336</issn><issn pub-type="epub">1945-5771</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26917112</article-id><article-id pub-id-type="pmc">5020348</article-id><article-id pub-id-type="publisher-id">1141468</article-id><article-id pub-id-type="doi">10.1080/15284336.2016.1141468</article-id><article-categories><subj-group subj-group-type="article-type"><subject>Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Overton</surname><given-names>Edgar Turner</given-names></name><xref ref-type="aff" rid="AFF0001">
<sup>a</sup>
</xref><xref ref-type="corresp" rid="COR0001">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tebas</surname><given-names>Pablo</given-names></name><xref ref-type="aff" rid="AFF0002">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Coate</surname><given-names>Bruce</given-names></name><xref ref-type="aff" rid="AFF0003">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ryan</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="AFF0003">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Perniciaro</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="AFF0004">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dayaram</surname><given-names>Yaswant K.</given-names></name><xref ref-type="aff" rid="AFF0004">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>De La Rosa</surname><given-names>Guy</given-names></name><xref ref-type="aff" rid="AFF0005">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Baugh</surname><given-names>Bryan P.</given-names></name><xref ref-type="aff" rid="AFF0005">
<sup>e</sup>
</xref></contrib><aff id="AFF0001"><label><sup>a</sup></label><institution><named-content content-type="department">Department of Medicine</named-content>, <named-content content-type="institution-name">University of Alabama School of Medicine</named-content></institution>, <named-content content-type="city">Birmingham</named-content>, <named-content content-type="state">AL</named-content>, <country>USA</country></aff><aff id="AFF0002"><label><sup>b</sup></label><institution><named-content content-type="department">Department of Medicine</named-content>, <named-content content-type="institution-name">University of Pennsylvania</named-content></institution>, <named-content content-type="city">Philadelphia</named-content>, <named-content content-type="state">PA</named-content>, <country>USA</country></aff><aff id="AFF0003"><label><sup>c</sup></label><institution><named-content content-type="institution-name">Janssen Research &#x00026; Development</named-content></institution>, <named-content content-type="city">Titusville</named-content>, <named-content content-type="state">NJ</named-content>, <country>USA</country></aff><aff id="AFF0004"><label><sup>d</sup></label><institution><named-content content-type="department">Janssen Scientific Affairs</named-content>, <named-content content-type="institution-name">LLC</named-content></institution>, <named-content content-type="city">Titusville</named-content>, <named-content content-type="state">NJ</named-content>, <country>USA</country></aff><aff id="AFF0005"><label><sup>e</sup></label><institution><named-content content-type="department">Janssen Global Services</named-content>, <named-content content-type="institution-name">LLC</named-content></institution>, <named-content content-type="city">Raritan</named-content>, <named-content content-type="state">NJ</named-content>, <country>USA</country></aff></contrib-group><author-notes><corresp id="COR0001"><label>* </label>Correspondence to: Edgar Turner Overton, MD, 908 20th St S, CCB Rm 330A, Birmingham, AL 35294 (205) 934&#x02013;5191. Email: <email>toverton@uab.edu</email></corresp></author-notes><pub-date pub-type="ppub"><day>3</day><month>3</month><year>2016</year><!--string-date: March 2016--></pub-date><pub-date pub-type="epub"><day>17</day><month>3</month><year>2016</year></pub-date><volume>17</volume><issue>2</issue><fpage seq="4">72</fpage><lpage>77</lpage><permissions><copyright-statement>&#x000a9; 2016 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="yhct-17-072.pdf"/><abstract><p>
<bold>Background</bold>: The phase 4, METABOLIK trial demonstrated that changes in metabolic parameters with darunavir with low-dose ritonavir (DRV/r) were comparable to those observed with atazanavir with low-dose ritonavir (ATV/r). A comprehensive assessment of the effects of these agents on insulin sensitivity will provide additional, relevant clinical information.</p><p>
<bold>Methods</bold>: In this substudy of METABOLIK, HIV-1&#x02013;infected, antiretroviral agent&#x02013;na&#x000ef;ve male subjects aged&#x000a0;&#x02265;18&#x000a0;years with a viral load of&#x000a0;&#x0003e;1,000 copies/mL were randomized to receive DRV/r 800/100&#x000a0;mg once daily (qd) or ATV/r 300/100&#x000a0;mg qd, both with a fixed dose of tenofovir disoproxil fumarate/emtricitabine 300/200&#x000a0;mg qd. The effects of DRV/r versus ATV/r on insulin sensitivity over 48&#x000a0;weeks were compared using the euglycemic hyperinsulinemic clamp, the preferred method to assess insulin sensitivity; primary end point was the effect on insulin sensitivity during the first 12&#x000a0;weeks.</p><p>
<bold>Results</bold>: Twenty-seven subjects completed the study. In the DRV/r arm (<italic>n</italic>&#x000a0;=&#x000a0;14), median glucose disposal from baseline through weeks 12 and 48 was 9.3, 11.4, and 9.9&#x000a0;mg/kg*min, respectively; in the ATV/r arm (<italic>n</italic>&#x000a0;=&#x000a0;13), these values were 8.9, 8.6, and 9.1&#x000a0;mg/kg*min, respectively. Median insulin sensitivity in the DRV/r arm at baseline, week 12, and week 48 was 24.0, 25.0, and 21.5&#x000a0;mg/kg*min per &#x003bc;IU/mL&#x02009;&#x000d7;&#x02009;100, respectively; these values in the ATV/r arm were 20.7, 22.0, and 22.0&#x000a0;mg/kg*min per &#x003bc;IU/mL&#x02009;&#x000d7;&#x02009;100, respectively. Most subjects had&#x000a0;&#x02265;1 adverse event, including three serious adverse events (<italic>n</italic>&#x000a0;=&#x000a0;2 [DRV/r], <italic>n</italic>&#x000a0;=&#x000a0;1 [ATV/r]).</p><p>
<bold>Conclusions</bold>: DRV/r and ATV/r displayed similar modest effects on insulin sensitivity using a euglycemic hyperinsulinemic clamp.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Darunavir</kwd><kwd>Human immunodeficiency virus (HIV)</kwd><kwd>Antiretroviral agents</kwd><kwd>Insulin sensitivity</kwd></kwd-group><counts><fig-count count="2"/><table-count count="2"/><equation-count count="0"/><ref-count count="33"/><page-count count="6"/></counts></article-meta></front><body><sec id="S0001"><title>Background</title><p>Some antiretroviral (ARV) agents, notably protease inhibitors (PIs), have been associated with metabolic complications and an increased risk of cardiovascular disease in human immunodeficiency virus (HIV)-1&#x02013;infected individuals.<xref rid="CIT0001" ref-type="bibr">
<sup>1&#x02212;5</sup>
</xref> The use of &#x0201c;older&#x0201d; PIs (particularly indinavir and lopinavir/ritonavir [LPV/r]) has been associated with worsening of lipid parameters,<xref rid="CIT0006" ref-type="bibr">
<sup>6&#x02212;10</sup>
</xref> increased inflammation,<xref rid="CIT0011" ref-type="bibr">
<sup>11</sup>
</xref> insulin resistance,<xref rid="CIT0006" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>,</sup>
<xref rid="CIT0012" ref-type="bibr">
<sup>12&#x02212;14</sup>
</xref> hyperglycemia, and diabetes mellitus.<xref rid="CIT0012" ref-type="bibr">
<sup>12</sup>
</xref> Atazanavir (ATV) has a favorable metabolic profile in HIV-1&#x02013;infected subjects, and is generally considered to be a &#x0201c;metabolically friendly&#x0201d; PI.<xref rid="CIT0015" ref-type="bibr">
<sup>15</sup>
</xref>
</p><p>Darunavir with low-dose ritonavir (DRV/r) 800/100&#x000a0;mg once daily (qd) in combination with other ARVs is approved for the treatment of HIV-1&#x02013;infected, ARV-na&#x000ef;ve, and ARV-experienced, adult subjects who do not harbor DRV resistance-associated mutations,<xref rid="CIT0016" ref-type="bibr">
<sup>16,17</sup>
</xref> and is one of the preferred agents in the United States Department of Health and Human Services guidelines for the treatment of ARV-na&#x000ef;ve individuals.<xref rid="CIT0018" ref-type="bibr">
<sup>18</sup>
</xref> The phase 4, randomized <underline>M</underline>etabolic <underline>E</underline>valuation in <underline>T</underline>reatment-na&#x000ef;ves <underline>A</underline>ssessing the impact of two <underline>BO</underline>osted protease inhibitors on <underline>LI</underline>pids and other mar<underline>K</underline>ers (METABOLIK) trial evaluated the metabolic outcomes, efficacy, and safety of DRV/r-based therapy compared with ATV/r-based therapy in treatment-na&#x000ef;ve, HIV-1&#x02013;infected subjects.<xref rid="CIT0019" ref-type="bibr">
<sup>19</sup>
</xref> Results from the METABOLIK trial revealed that changes in metabolic parameters with DRV/r were comparable to changes observed with ATV/r, with no differences in lipid parameters, fasting glucose, or insulin sensitivity (as measured by the homeostasis model assessment of insulin resistance [HOMA-IR] method).</p><p>The euglycemic hyperinsulinemic clamp (EHC) technique is considered the gold standard for the evaluation of insulin resistance.<xref rid="CIT0020" ref-type="bibr">
<sup>20</sup>
</xref> As opposed to HOMA-IR, which is a surrogate of basal insulin sensitivity only, EHC facilitates a dynamic quantitative assessment of overall insulin sensitivity for the entire body by directly assessing glucose utilization as mediated by insulin under steady state conditions.<xref rid="CIT0021" ref-type="bibr">
<sup>21,22</sup>
</xref> A number of small studies (n&#x000a0;&#x02264;30) have used this technique to evaluate insulin resistance with the use of PIs (including LPV/r, ATV, and indinavir), primarily in HIV-uninfected subjects.<xref rid="CIT0023" ref-type="bibr">
<sup>23&#x02212;26</sup>
</xref> A few small studies (n&#x000a0;&#x02264;27) have also evaluated insulin resistance with PIs using the EHC in HIV-1&#x02013;infected subjects;<xref rid="CIT0027" ref-type="bibr">
<sup>27&#x02212;29</sup>
</xref> however, DRV/r has not been evaluated with this technique.</p><p>The present substudy of the METABOLIK trial was designed to evaluate the effects of DRV/r and ATV/r with fixed-dose tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) on insulin sensitivity using the EHC in treatment-na&#x000ef;ve, HIV-1&#x02013;infected adults over 48&#x000a0;weeks.</p></sec><sec sec-type="MaterialsAndMethods" id="S0002"><title>Methods</title><p>The METABOLIK substudy was a phase 4, multicenter, open-label, randomized study; details of the study design have been presented in detail previously.<xref rid="CIT0019" ref-type="bibr">
<sup>19</sup>
</xref> In brief, eligible subjects were at least 18&#x000a0;years of age, na&#x000ef;ve to ARV therapy (defined as no previous ARV therapy for&#x000a0;&#x0003e;10&#x000a0;days), and had plasma HIV-1 RNA&#x000a0;&#x02265;1,000 copies/mL. Subjects were required to be infected with HIV sensitive to DRV, ATV, TDF, and FTC. Key exclusion criteria included body mass index&#x000a0;&#x0003e;30&#x000a0;kg/m<sup>2</sup>, fasting glucose&#x000a0;&#x0003e;100&#x000a0;mg/dL, low-density lipoprotein cholesterol&#x000a0;&#x0003e;130&#x000a0;mg/dL, triglycerides&#x000a0;&#x0003e;200&#x000a0;mg/dL, and presence of active AIDS defining illness (defined as category C conditions based on the Centers for Disease Control and Prevention Classification System for HIV infection),<xref rid="CIT0013" ref-type="bibr">
<sup>13</sup>
</xref> except stable cutaneous Kaposi&#x02019;s sarcoma or wasting syndrome.</p><p>The study was approved by institutional review boards at all clinical sites, and was conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. All subjects provided written informed consent.</p><p>Initially, up to 20 subjects from the main study (with complete week 48 evaluations) were to be enrolled in this substudy; however, as only 8 subjects participating in the main study were enrolled, the enrollment period and size of the METABOLIK substudy were extended to reach a target of 10 subjects per arm. Subjects were randomized in a 1:1 ratio to receive DRV/r 800/100&#x000a0;mg qd or ATV/r 300/100&#x000a0;mg qd, both with the fixed-dose combination of TDF/FTC 300/200&#x000a0;mg qd (Fig. <xref rid="F0001" ref-type="fig">1</xref>). Use of lipid-lowering agents, including over-the-counter medications, was prohibited from 28&#x000a0;days prior to baseline through week 12 of the trial. Atorvastatin and rosuvastatin were allowed after week 12.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1 </label><caption><p>Study design.</p></caption><graphic xlink:href="yhct_a_1141468_f0001_b"/><attrib>ARV, antiretroviral; ATV, atazanavir; DRV, darunavir; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine; r, low-dose ritonavir; qd, once daily. <sup>a</sup>29 subjects due to over-enrollment. <sup>b</sup>14 subjects due to over-enrollment. <sup>c</sup>15 subjects due to over-enrollment. Two subjects withdrew before treatment initiation.</attrib></fig><p>The primary end point was the effect of DRV/r qd and ATV/r qd on insulin sensitivity during the first 12&#x000a0;weeks of therapy using the EHC technique.<xref rid="CIT0021" ref-type="bibr">
<sup>21,30</sup>
</xref> A secondary end point was the effect of DRV/r qd and ATV/r qd on insulin sensitivity at week 48 using the EHC technique. Safety analyses, including laboratory safety assessments (chemistry, liver function tests, hematology), vital signs and physical examination, and incidence of overall adverse events (AEs) and HIV-related events, were recorded throughout the substudy. Viral suppression at week 48 was calculated using the confirmed virologic response rate algorithm (HIV-1 RNA&#x000a0;&#x0003c;50 copies/mL),<xref rid="CIT0019" ref-type="bibr">
<sup>19</sup>
</xref> which is an adaptation of the time to loss of virologic response algorithm that classifies subjects with confirmed resuppression after virologic failure as virologic successes.<xref rid="CIT0031" ref-type="bibr">
<sup>31</sup>
</xref>
</p><p>The EHC technique was performed by clamping or maintaining a predetermined blood glucose level, and the measurement was accomplished by clamping insulin at a constant rate of 40&#x000a0;mU/m<sup>2</sup>/min for the duration of the procedure and infusing glucose 20% at a rate titrated according to blood glucose. Prior to receiving the insulin clamp, subjects were required to abstain from vigorous exercise and to consume at least 150&#x000a0;g of carbohydrates for 3&#x000a0;days prior to the clamp procedure. They then fasted for 20&#x000a0;h prior to the clamp procedure. An intravenous catheter with normal saline was applied in one arm, and a retrograde draw line was inserted in the other arm. Both glucose and insulin were infused simultaneously. Blood samples to measure insulin were collected at the beginning of the procedure (<italic>t</italic>&#x000a0;=&#x000a0;0) and at seven subsequent time points (<italic>t</italic>&#x000a0;=&#x000a0;10&#x000a0;min, <italic>t</italic>&#x000a0;=&#x000a0;20&#x000a0;min, <italic>t</italic>&#x000a0;=&#x000a0;30&#x000a0;min, <italic>t</italic>&#x000a0;=&#x000a0;3&#x000a0;h, <italic>t</italic>&#x000a0;=&#x000a0;3&#x000a0;h and 10&#x000a0;min, <italic>t</italic>&#x000a0;=&#x000a0;3&#x000a0;h and 20&#x000a0;min, <italic>t</italic>&#x000a0;=&#x000a0;3&#x000a0;h and 30&#x000a0;min). Glucose was measured 10&#x000a0;min prior to the beginning of the procedure (<italic>t</italic>&#x000a0;=&#x000a0;&#x02013;10&#x000a0;min), at the beginning of the procedure (<italic>t</italic>&#x000a0;=&#x000a0;0), every 5&#x000a0;min from <italic>t</italic>&#x000a0;=&#x000a0;30&#x000a0;min to <italic>t</italic>&#x000a0;=&#x000a0;90&#x000a0;min, and every 10&#x000a0;min from <italic>t</italic>&#x000a0;=&#x000a0;90 until completion of the procedure (<italic>t</italic>&#x000a0;=&#x000a0;3&#x000a0;h and 30&#x000a0;min). Insulin infusion (100 units of insulin added to 200&#x000a0;cc of normal saline) was started at <italic>t</italic>&#x000a0;=&#x000a0;30&#x000a0;min, along with dextrose 20% solution at 50&#x000a0;mL/h, until completion of the procedure. Blood glucose was maintained at 100&#x000a0;mg/dL during the procedure.</p><p>No sample size calculations were performed; however, a sample size of 20 subjects was deemed sufficient to clinically assess the substudy end points. Post hoc, it was estimated that the study was powered to detect a difference in the change in glucose disposal rate&#x000a0;&#x02265;3.0&#x000a0;mg/kg min between the two groups at the week 12 time point, based on the standard deviation of the baseline glucose disposal rate of 2.49&#x000a0;mg/kg*min, <italic>&#x003b1;</italic>&#x000a0;=&#x000a0;0.05, and <italic>&#x003b2;</italic>&#x000a0;=&#x000a0;0.20. Data were analyzed by treatment group using summary statistics. Continuous variables were summarized using descriptive statistics (n, mean, standard deviation, median, minimum, and maximum). Categorical variables are presented using frequency distributions.</p></sec><sec sec-type="results" id="S0003"><title>Results</title><sec id="S0004"><title>Study population and baseline characteristics</title><p>Twenty-nine subjects participated in the study; two subjects were not included in the analysis because they withdrew before the initiation of treatment. Of the remaining 27 subjects, 14 subjects received DRV/r-based regimens and 13 received ATV/r-based regimens. Twenty-two subjects (81.5%) completed the week 48 evaluations: 12 were in the DRV/r arm and 10 were in the ATV/r arm. Additional details on subject disposition are provided in Table <xref rid="T0001" ref-type="table">1</xref>.</p><table-wrap id="T0001" orientation="portrait" position="float"><label>Table 1 </label><caption><title>Subject disposition</title></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr valign="top"><th align="left" valign="top">&#x000a0;</th><th align="center" valign="top"><bold>DRV/r (<italic>n</italic> = 14)</bold></th><th align="center" valign="top"><bold>ATV/r (<italic>n</italic> = 15)</bold></th><th align="center" valign="top"><bold>Overall (<italic>n</italic> = 29)</bold></th></tr></thead><tbody><tr valign="top"><td align="left" valign="top">Randomized and not treated, n</td><td align="left" valign="top">0</td><td align="left" valign="top">2</td><td align="left" valign="top">2</td></tr><tr valign="top"><td align="left" valign="top">Intent-to-treat set, n</td><td align="left" valign="top">14</td><td align="left" valign="top">13</td><td align="left" valign="top">27</td></tr><tr valign="top"><td align="left" valign="top">&#x02003;EHC-evaluable set, <italic>n</italic> (%)</td><td align="left" valign="top">12 (86)</td><td align="left" valign="top">12 (92)</td><td align="left" valign="top">24 (89)</td></tr><tr valign="top"><td align="left" valign="top">&#x02003;Completed week 12 study visit, <italic>n</italic> (%)</td><td align="left" valign="top">13 (93)</td><td align="left" valign="top">12 (92)</td><td align="left" valign="top">25 (93)</td></tr><tr valign="top"><td align="left" valign="top">&#x02003;Completed study, <italic>n</italic> (%)</td><td align="left" valign="top">12 (86)</td><td align="left" valign="top">10 (77)</td><td align="left" valign="top">22 (82)</td></tr><tr valign="top"><td align="left" valign="top">&#x02003;Discontinued study, <italic>n</italic> (%)</td><td align="left" valign="top">2 (14)</td><td align="left" valign="top">3 (23)</td><td align="left" valign="top">5 (19)</td></tr><tr valign="top"><td align="left" valign="top">Reason for discontinuing study</td><td align="left" valign="top">&#x000a0;</td><td align="left" valign="top">&#x000a0;</td><td align="left" valign="top">&#x000a0;</td></tr><tr valign="top"><td align="left" valign="top">&#x02003;Adverse event, <italic>n</italic> (%)</td><td align="left" valign="top">0</td><td align="left" valign="top">1 (8)</td><td align="left" valign="top">1 (4)</td></tr><tr valign="top"><td align="left" valign="top">&#x02003;Ineligible to continue the study, <italic>n</italic> (%)</td><td align="left" valign="top">0</td><td align="left" valign="top">1 (8)</td><td align="left" valign="top">1 (4)</td></tr><tr valign="top"><td align="left" valign="top">&#x02003;Other,<xref rid="TFN0002" ref-type="table-fn">
<sup>a</sup>
</xref><italic>n</italic> (%)</td><td align="left" valign="top">2 (14)</td><td align="left" valign="top">1 (8)</td><td align="left" valign="top">3 (11)</td></tr></tbody></table><table-wrap-foot><fn id="TFN0001"><p>Note: DRV, darunavir; r, low-dose ritonavir; ATV, atazanavir; EHC, euglycemic hyperinsulinemic clamp.</p></fn><fn id="TFN0002"><label><sup>a</sup></label><p>Two subjects on DRV were incarcerated, and there was a dispensing error for the subject on ATV.</p></fn></table-wrap-foot></table-wrap><p>All subjects were male, with a median age of 29&#x000a0;years (range: 20&#x02013;47 years) in the DRV/r arm and 26&#x000a0;years (range: 20&#x02013;48 years) in the ATV/r arm. The majority of subjects were Black or African American: 57% in the DRV/r arm and 62% in the ATV/r arm. Additional baseline characteristics are provided in Table <xref rid="T0002" ref-type="table">2</xref>.</p><table-wrap id="T0002" orientation="portrait" position="float"><label>Table 2 </label><caption><title>Demographics and baseline characteristics of subjects who initiated therapy</title></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*" char="."/><col width="1*" char="."/></colgroup><thead><tr valign="top"><th align="left" valign="top">&#x000a0;</th><th align="center" valign="top" char="."><bold>DRV/r (<italic>n</italic> = 14)</bold></th><th align="center" valign="top" char="."><bold>ATV/r (<italic>n</italic> = 13)</bold></th></tr></thead><tbody><tr valign="top"><td align="left" valign="top">Median age, years (range)</td><td align="char" valign="top" char=".">29 (20&#x02013;47)</td><td align="char" valign="top" char=".">26 (20&#x02013;48)</td></tr><tr valign="top"><td align="left" valign="top">Male, n (%)</td><td align="char" valign="top" char=".">14 (100)</td><td align="char" valign="top" char=".">13 (100)</td></tr><tr valign="top"><td align="left" valign="top">Race, n (%)</td><td align="left" valign="top" char=".">&#x000a0;</td><td align="left" valign="top" char=".">&#x000a0;</td></tr><tr valign="top"><td align="left" valign="top">&#x02003;Black or African American</td><td align="char" valign="top" char=".">8 (57)</td><td align="char" valign="top" char=".">8 (62)</td></tr><tr valign="top"><td align="left" valign="top">&#x02003;White</td><td align="char" valign="top" char=".">6 (43)</td><td align="char" valign="top" char=".">4 (31)</td></tr><tr valign="top"><td align="left" valign="top">&#x02003;American Indian or Alaska Native</td><td align="char" valign="top" char=".">0</td><td align="char" valign="top" char=".">1 (8)</td></tr><tr valign="top"><td align="left" valign="top">Median BMI, kg/m<sup>2</sup> (range)</td><td align="char" valign="top" char=".">24.1 (21.5&#x02013;25.6)</td><td align="char" valign="top" char=".">23.4 (18.6&#x02013;30.8)</td></tr><tr valign="top"><td align="left" valign="top">Median total cholesterol, mg/dL (range)<xref rid="TFN0004" ref-type="table-fn">
<sup>a</sup>
</xref></td><td align="char" valign="top" char=".">138.5 (94&#x02013;173)</td><td align="char" valign="top" char=".">140 (105&#x02013;218)</td></tr><tr valign="top"><td align="left" valign="top">Median LDL cholesterol, mg/dL (range)<xref rid="TFN0004" ref-type="table-fn">
<sup>a</sup>
</xref></td><td align="char" valign="top" char=".">81.5 (36&#x02013;114)</td><td align="char" valign="top" char=".">82 (55&#x02013;145)</td></tr><tr valign="top"><td align="left" valign="top">Median HDL cholesterol, mg/dL (range)<xref rid="TFN0004" ref-type="table-fn">
<sup>a</sup>
</xref></td><td align="char" valign="top" char=".">44 (27&#x02013;59)</td><td align="char" valign="top" char=".">42 (29&#x02013;57)</td></tr><tr valign="top"><td align="left" valign="top">Median triglycerides, mg/dL (range)<xref rid="TFN0004" ref-type="table-fn">
<sup>a</sup>
</xref></td><td align="char" valign="top" char=".">88.5 (50&#x02013;235)</td><td align="char" valign="top" char=".">91 (53&#x02013;330)</td></tr><tr valign="top"><td align="left" valign="top">Median glucose, mg/dL (range)<xref rid="TFN0004" ref-type="table-fn">
<sup>a</sup>
</xref></td><td align="char" valign="top" char=".">85 (70&#x02013;103)</td><td align="char" valign="top" char=".">91 (85&#x02013;95)</td></tr><tr valign="top"><td align="left" valign="top">Median insulin, mIU/L (range)<xref rid="TFN0004" ref-type="table-fn">
<sup>a</sup>
</xref></td><td align="char" valign="top" char=".">1.9 (1.9&#x02013;9.6)</td><td align="char" valign="top" char=".">1.9 (1.9&#x02013;19.1)</td></tr><tr valign="top"><td align="left" valign="top">Median CD4 count (range)</td><td align="char" valign="top" char=".">234 (23&#x02013;619)</td><td align="char" valign="top" char=".">271 (77&#x02013;524)</td></tr><tr valign="top"><td align="left" valign="top">Mean log<sub>10</sub> HIV-1 RNA, copies/mL (SD)</td><td align="char" valign="top" char=".">5.11 (0.69)</td><td align="char" valign="top" char=".">4.77 (0.45)</td></tr></tbody></table><table-wrap-foot><fn id="TFN0003"><p>Note: DRV, darunavir; r, low-dose ritonavir; ATV, atazanavir; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HIV, human immunodeficiency virus; SD, standard deviation.</p></fn><fn id="TFN0004"><label><sup>a</sup></label><p>Measured from fasting samples.</p></fn></table-wrap-foot></table-wrap></sec><sec id="S0005"><title>Measures of insulin sensitivity</title><p>In the DRV/r arm, the median (min&#x02013;max) glucose disposal rate (GDR) increased from baseline (9.3 [5&#x02013;14] mg/kg*min) to week 12 (11.4 [7&#x02013;14] mg/kg*min) and modestly at week 48 (9.9 [8&#x02013;19] mg/kg*min); in the ATV/r arm, median GDR stayed relatively stable from baseline (8.9 [4&#x02013;14] mg/kg*min) through week 12 (8.6 [5&#x02013;14] mg/kg*min) and week 48 (9.1 [6&#x02013;16] mg/kg*min; <bold>Fig.</bold>
<xref rid="F0002" ref-type="fig">2</xref>A). From baseline to week 12, median (range) insulin sensitivity increased modestly in both arms: from 24.0 (10&#x02013;32) to 25.0 (12&#x02013;175) mg/kg*min per &#x003bc;IU/mL&#x02009;&#x000d7;&#x02009;100 in the DRV/r arm, and from 20.7 (10&#x02013;35) to 22.2 (10&#x02013;29) mg/kg*min per &#x003bc;IU/mL&#x02009;&#x000d7;&#x02009;100 in the ATV/r arm (<bold>Fig.</bold>
<xref rid="F0002" ref-type="fig">2</xref>B). Median (range) insulin sensitivity declined by 48&#x000a0;weeks in the DRV/r arm (21.5 [14&#x02013;48] mg/kg*min per &#x003bc;IU/mL&#x02009;&#x000d7;&#x02009;100), whereas it was stable in the ATV/r arm (22.0 [11&#x02013;36] mg/kg*min per &#x003bc;IU/mL&#x02009;&#x000d7;&#x02009;100; Fig. <xref rid="F0002" ref-type="fig">2</xref>B). The differences in the changes in glucose disposal rate and insulin sensitivity were not significantly different between the DRV/r and ATV/r arms.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2 </label><caption><p>Clamp analyses at baseline, week 12, and week 48: (A) glucose disposal rate and (B) insulin sensitivity.<sup>a</sup>
</p></caption><graphic xlink:href="yhct_a_1141468_f0002_b"/><attrib>DRV, darunavir; r, low-dose ritonavir; ATV, atazanavir; W12, week 12; W48, week 48; IQR, interquartile range. <sup>a</sup>The boxes and horizontal lines reflect the IQR and median values, respectively. The vertical lines reflect the 5th and 95th percentiles. There is one outlier in the DRV/r group at the week 48 time point. The week 12 insulin sensitivity value of 174.8&#x000a0;mg/kg*min per &#x003bc;IU/mL&#x02009;&#x000d7;&#x02009;100 in the ATV/r group is not displayed (outlier).</attrib></fig></sec><sec id="S0006"><title>Safety evaluations</title><p>Nearly all the subjects in the DRV/r (86%) and ATV/r (92%) arms had at least one treatment-emergent AE. Two subjects in the DRV/r (14.3%) arm reported serious treatment-emergent AEs, compared with one subject in the ATV/r (7.7%) arm. These three serious AEs were a case of bronchitis/pneumonia, an incident diagnosis of diabetes, and a case of purpura; all three were determined by the site investigator to be unrelated to study treatment. The incidence of AEs, at least possibly related to study medication, was 50% in the DRV/r arm compared with 77% in the ATV/r arm, the difference related primarily to elevated bilirubin. Over the 48&#x000a0;weeks, there were no clinically relevant differences in safety parameters between the DRV/r and ATV/r arms other than the expected differences in bilirubin levels in the ATV/r arm.<xref rid="CIT0018" ref-type="bibr">
<sup>18</sup>
</xref>
</p></sec><sec id="S0007"><title>Viral load outcomes</title><p>Viral load improved over the course of the study. Mean log<sub>10</sub> HIV-1 RNA decreased from baseline to week 48 in both the DRV/r (change of &#x02013;3.4 copies/mL) and ATV/r (change of &#x02013;3.1 copies/mL) arms. At week 48, 91.7% (11/12) of DRV/r-treated subjects and 77.8% (7/9) of ATV/r-treated subjects had HIV-1 RNA&#x000a0;&#x0003c;50 copies/mL (100.0% and 100.0% had&#x000a0;&#x0003c;400 copies/mL in the DRV/r and ATV/r arms, respectively).</p></sec></sec><sec sec-type="discussion" id="S0008"><title>Discussion</title><p>These results demonstrate that both DRV/r and ATV/r produce similar modest changes in GDR and insulin sensitivity over 48&#x000a0;weeks, as measured by the EHC technique. GDR values were normal at baseline, defined previously as a value&#x000a0;&#x0003e;4.7&#x000a0;mg/kg*min, and were stable over 48&#x000a0;weeks in both arms.<xref rid="CIT0032" ref-type="bibr">
<sup>32</sup>
</xref> When accounting for insulin concentrations, insulin sensitivity improved modestly over 12&#x000a0;weeks and was stable over 48 weeks in both treatment arms. There were no clinically relevant differences in safety or viral suppression for either DRV/r-treated subjects or ATV/r-treated subjects.</p><p>Using EHC, certain PIs, specifically LPV/r and indinavir, have been associated with insulin resistance in healthy subjects,<xref rid="CIT0023" ref-type="bibr">
<sup>23,24</sup>
</xref> although the effect of LPV/r was not confirmed in subsequent studies.<xref rid="CIT0025" ref-type="bibr">
<sup>25,26</sup>
</xref> ATV has been shown to have minimal impact on insulin sensitivity in HIV-negative subjects,<xref rid="CIT0023" ref-type="bibr">
<sup>23,25</sup>
</xref> and changing PI therapy to ATV/r improved PI-induced insulin resistance in HIV-1&#x02013;infected men.<xref rid="CIT0027" ref-type="bibr">
<sup>27</sup>
</xref> These latter results have led to the general assumption that ATV has the best metabolic profile of the available PIs. This study, the first to evaluate the use of DRV/r with the EHC technique, suggests that the effects of DRV/r on insulin/glucose metabolism are comparable to those of ATV/r. The results of this substudy are consistent with the main METABOLIK trial , which used HOMA-IR as a surrogate measure of insulin resistance.<xref rid="CIT0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p><p>Changes in metabolic parameters from baseline to week 48 in the DRV/r arm were comparable with those previously observed with ATV/r in ARV-na&#x000ef;ve, HIV-1&#x02013;infected subjects in the CASTLE study.<xref rid="CIT0015" ref-type="bibr">
<sup>15</sup>
</xref> These results are also consistent with those seen in a phase 1 trial of DRV, which showed similar changes in fasting glucose parameters between DRV/r and ATV/r treatment groups, following 7&#x000a0;days of ritonavir and 21&#x000a0;days of DRV/r or ATV/r treatment.<xref rid="CIT0033" ref-type="bibr">
<sup>33</sup>
</xref>
</p><p>To date, this is one of the largest EHC studies conducted in HIV-1&#x02013;infected subjects initiating treatment with ARVs. Despite being one of the largest studies to use the EHC technique for the evaluation of insulin sensitivity in HIV-1&#x02013;infected subjects, this study is limited by its relatively small sample size and its limited ability to detect differences between the study arms. The small sample size also prohibited analyses that were adjusted based on baseline characteristics.</p></sec><sec sec-type="conclusions" id="S0009"><title>Conclusions</title><p>This substudy of the METABOLIK trial demonstrated similar modest changes in glucose disposal rates and insulin sensitivity over 48&#x000a0;weeks using DRV/r and ATV/r, as measured by the EHC technique. These data suggest a favorable insulin sensitivity profile for both DRV/r and ATV/r.</p></sec><sec id="S0010"><title>Author description</title><p>ETO developed the protocol, served as an investigator on the protocol, oversaw data collection, assisted with data analysis, and participated in drafting and editing the manuscript. PT served as an investigator on the protocol, assisted with data collection and data analysis, and participated in drafting and editing the manuscript. BC, RR, AP, YKD, GDLR, and BPB conceived and designed the experiments, analyzed the data, and participated in drafting and editing the manuscript. All authors read and approved the final manuscript.</p><p>
<bold>Clinical Trial registration:</bold> NCT00757783</p></sec><sec id="S0011"><title>Disclosure statement</title><p>ETO has served as a consultant for Gilead. PT has been a consultant for Merck and Gilead, serves on an adjudication committee for a GlaxoSmithKline vaccine study, and gave a continuing medical education talk in Spain that was sponsored by Janssen. BC was a full-time contract employee for Janssen at the time this study was conducted. RR, AP, YKD, GDLR, and BPB are employees of Janssen and stockholders of Johnson &#x00026; Johnson. The METABOLIK trial was sponsored by Janssen Therapeutics.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors would like to thank the subjects and their families<bold>,</bold> the principal investigators (Carl Fichtenbaum, Nur Onen, Edgar T Overton, Frank Rhame, and Pablo Tebas)<bold>,</bold> the METABOLIK substudy Janssen study team, and the study center staff for their participation in the substudy. Editorial support for this manuscript was provided by Courtney St. Amour, PhD, of MedErgy, and was funded by Janssen.</p></ack><ref-list><title>References</title><ref id="CIT0001"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murphy</surname><given-names>RL</given-names></name><name><surname>Berzins</surname><given-names>B</given-names></name><name><surname>Zala</surname><given-names>C</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy</article-title>
<source><italic>AIDS</italic></source>
<year>2010</year>
<volume>24</volume>
<fpage>885</fpage>
<lpage>890</lpage>
<pub-id pub-id-type="doi">10.1097/QAD.0b013e3283352ed5</pub-id>
<pub-id pub-id-type="pmid">19952712</pub-id></element-citation></ref><ref id="CIT0002"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Overton</surname><given-names>ET</given-names></name><name><surname>Arathoon</surname><given-names>E</given-names></name><name><surname>Baraldi</surname><given-names>E</given-names></name><name><surname>Tomaka</surname><given-names>F</given-names></name></person-group>
<article-title>Effect of darunavir on lipid profile in HIV-infected patients</article-title>
<source><italic>HIV Clin Trials</italic></source>
<year>2012</year>
<volume>13</volume>
<fpage>256</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="doi">10.1310/hct1305-256</pub-id>
<pub-id pub-id-type="pmid">23134626</pub-id></element-citation></ref><ref id="CIT0003"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Friis-M&#x000f8;ller</surname><given-names>N</given-names></name><name><surname>Weber</surname><given-names>R</given-names></name><name><surname>Reiss</surname><given-names>P</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Cardiovascular disease risk factors in HIV patients &#x02013; association with antiretroviral therapy. Results from the DAD study.</article-title>
<source><italic>AIDS</italic></source>
<year>2003</year>
<volume>17</volume>
<fpage>1179</fpage>
<lpage>1193</lpage>
<pub-id pub-id-type="doi">10.1097/00002030-200305230-00010</pub-id>
<pub-id pub-id-type="pmid">12819520</pub-id></element-citation></ref><ref id="CIT0004"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Friis-M&#x000f8;ller</surname><given-names>N</given-names></name><name><surname>Ryom</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The data-collection on adverse effects of anti-HIV drugs (D:A:D) study</article-title>
<source><italic>Eur J Prev Cardiol</italic></source>
<year>2015</year>
<comment>Epub ahead of print</comment>
</element-citation></ref><ref id="CIT0005"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kitahata</surname><given-names>MM</given-names></name><name><surname>Rodriguez</surname><given-names>B</given-names></name><name><surname>Haubrich</surname><given-names>R</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Cohort profile: The centers for AIDS Research Network of Integrated Clinical Systems</article-title>
<source><italic>Int J Epidemiol</italic></source>
<year>2008</year>
<volume>37</volume>
<fpage>948</fpage>
<lpage>955</lpage>
<pub-id pub-id-type="doi">10.1093/ije/dym231</pub-id>
<pub-id pub-id-type="pmid">18263650</pub-id></element-citation></ref><ref id="CIT0006"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Behrens</surname><given-names>G</given-names></name><name><surname>Dejam</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors</article-title>
<source><italic>AIDS</italic></source>
<year>1999</year>
<volume>13</volume>
<fpage>F63</fpage>
<lpage>F70</lpage>
<pub-id pub-id-type="doi">10.1097/00002030-199907090-00001</pub-id>
<pub-id pub-id-type="pmid">10416516</pub-id></element-citation></ref><ref id="CIT0007"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Flint</surname><given-names>OP</given-names></name><name><surname>Noor</surname><given-names>MA</given-names></name><name><surname>Hruz</surname><given-names>PW</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: Cellular mechanisms and clinical implications</article-title>
<source><italic>Toxicol Pathol</italic></source>
<year>2009</year>
<volume>37</volume>
<fpage>65</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1177/0192623308327119</pub-id>
<pub-id pub-id-type="pmid">19171928</pub-id></element-citation></ref><ref id="CIT0008"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stein</surname><given-names>JH</given-names></name><name><surname>Komarow</surname><given-names>L</given-names></name><name><surname>Cotter</surname><given-names>BR</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Lipoprotein changes in HIV-infected antiretroviral-na&#x000ef;ve individuals after starting antiretroviral therapy: ACTG study A5152s Stein: lipoprotein changes on antiretroviral therapy</article-title>
<source><italic>J Clin Lipidol</italic></source>
<year>2008</year>
<volume>2</volume>
<fpage>464</fpage>
<lpage>471</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacl.2008.08.442</pub-id>
<pub-id pub-id-type="pmid">19956354</pub-id></element-citation></ref><ref id="CIT0009"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gotti</surname><given-names>D</given-names></name><name><surname>Cesana</surname><given-names>BM</given-names></name><name><surname>Albini</surname><given-names>L</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-na&#x000ef;ve patients prescribed efavirenz compared to atazanavir/ritonavir</article-title>
<source><italic>HIV Clin Trials</italic></source>
<year>2012</year>
<volume>13</volume>
<fpage>245</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="doi">10.1310/hct1305-245</pub-id>
<pub-id pub-id-type="pmid">23134625</pub-id></element-citation></ref><ref id="CIT0010"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ofotokun</surname><given-names>I</given-names></name><name><surname>Na</surname><given-names>LH</given-names></name><name><surname>Landovitz</surname><given-names>RJ</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257</article-title>
<source><italic>Clin Infect Dis</italic></source>
<year>2015</year>
<volume>60</volume>
<fpage>1842</fpage>
<lpage>1851</lpage>
<pub-id pub-id-type="doi">10.1093/cid/civ193</pub-id>
<pub-id pub-id-type="pmid">25767256</pub-id></element-citation></ref><ref id="CIT0011"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Jarujaron</surname><given-names>S</given-names></name><name><surname>Gurley</surname><given-names>EC</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>HIV protease inhibitors increase TNF-&#x003b1; and IL-6 expression in macrophages: Involvement of the RNA-binding protein HuR</article-title>
<source><italic>Atherosclerosis</italic></source>
<year>2007</year>
<volume>195</volume>
<fpage>e134</fpage>
<lpage>e143</lpage>
<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2007.04.008</pub-id>
<pub-id pub-id-type="pmid">17531241</pub-id></element-citation></ref><ref id="CIT0012"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yarasheski</surname><given-names>KE</given-names></name><name><surname>Tebas</surname><given-names>P</given-names></name><name><surname>Sigmund</surname><given-names>C</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Insulin resistance in HIV protease inhibitor-associated diabetes</article-title>
<source><italic>J Acquir Immune Defic Syndr</italic></source>
<year>1999</year>
<volume>21</volume>
<fpage>209</fpage>
<lpage>216</lpage>
<pub-id pub-id-type="doi">10.1097/00126334-199907010-00005</pub-id>
<pub-id pub-id-type="pmid">10421244</pub-id></element-citation></ref><ref id="CIT0013"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dub&#x000e9;</surname><given-names>MP</given-names></name></person-group>
<article-title>Disorders of glucose metabolism in patients infected with Human Immunodeficiency Virus</article-title>
<source><italic>Clin Infect Dis</italic></source>
<year>2000</year>
<volume>31</volume>
<fpage>1467</fpage>
<lpage>1475</lpage>
<pub-id pub-id-type="doi">10.1086/cid.2000.31.issue-6</pub-id>
<pub-id pub-id-type="pmid">11096014</pub-id></element-citation></ref><ref id="CIT0014"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walli</surname><given-names>R</given-names></name><name><surname>Herfort</surname><given-names>O</given-names></name><name><surname>Michl</surname><given-names>GM</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients</article-title>
<source><italic>AIDS</italic></source>
<year>1998</year>
<volume>12</volume>
<fpage>F167</fpage>
<lpage>F173</lpage>
<pub-id pub-id-type="doi">10.1097/00002030-199815000-00001</pub-id>
<pub-id pub-id-type="pmid">9814858</pub-id></element-citation></ref><ref id="CIT0015"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Molina</surname><given-names>JM</given-names></name><name><surname>Andrade-Villanueva</surname><given-names>J</given-names></name><name><surname>Echevarria</surname><given-names>J</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study</article-title>
<source><italic>J Acquir Immune Defic Syndr</italic></source>
<year>2010</year>
<volume>53</volume>
<fpage>323</fpage>
<lpage>332</lpage>
<pub-id pub-id-type="doi">10.1097/QAI.0b013e3181c990bf</pub-id>
<pub-id pub-id-type="pmid">20032785</pub-id></element-citation></ref><ref id="CIT0016"><element-citation publication-type="book">
<person-group person-group-type="author"><collab>PREZISTA<sup>&#x000ae;</sup> (darunavir)</collab></person-group>
<publisher-loc>Titusville, NJ</publisher-loc>
<publisher-name>Janssen Therapeutics</publisher-name>
<month>5</month>
<year>2015</year>
</element-citation></ref><ref id="CIT0017"><element-citation publication-type="standard">
<person-group person-group-type="author"><collab>PREZISTA<sup>&#x000ae;</sup> (darunavir)</collab></person-group>
<source>EPARs for authorized medicinal products for human use</source>
<month>12</month>
<year>2015</year>
</element-citation></ref><ref id="CIT0018"><element-citation publication-type="web">
<person-group person-group-type="author"><collab>Panel on Antiretroviral Guidelines for Adults and Adolescents.</collab></person-group>
<comment>Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.</comment>
<ext-link ext-link-type="uri" xlink:href="https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf">https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf</ext-link>
<date-in-citation>June 11, 2015.</date-in-citation>
</element-citation></ref><ref id="CIT0019"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aberg</surname><given-names>JA</given-names></name><name><surname>Tebas</surname><given-names>P</given-names></name><name><surname>Overton</surname><given-names>ET</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks</article-title>
<source><italic>AIDS Res Hum Retroviruses</italic></source>
<year>2012</year>
<volume>28</volume>
<fpage>1184</fpage>
<lpage>1195</lpage>
<pub-id pub-id-type="doi">10.1089/aid.2011.0327</pub-id>
<pub-id pub-id-type="pmid">22352336</pub-id></element-citation></ref><ref id="CIT0020"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tam</surname><given-names>CS</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Johnson</surname><given-names>WD</given-names></name><name><surname>Cefalu</surname><given-names>WT</given-names></name><name><surname>Redman</surname><given-names>LM</given-names></name><name><surname>Ravussin</surname><given-names>E</given-names></name></person-group>
<article-title>Defining insulin resistance from hyperinsulinemic-euglycemic clamps</article-title>
<source><italic>Diabet Care</italic></source>
<year>2012</year>
<volume>35</volume>
<fpage>1605</fpage>
<lpage>1610</lpage>
<pub-id pub-id-type="doi">10.2337/dc11-2339</pub-id>
</element-citation></ref><ref id="CIT0021"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wallace</surname><given-names>TM</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name></person-group>
<article-title>The assessment of insulin resistance in man</article-title>
<source><italic>Diabet Med</italic></source>
<year>2002</year>
<volume>19</volume>
<fpage>527</fpage>
<lpage>534</lpage>
<pub-id pub-id-type="doi">10.1046/j.1464-5491.2002.00745.x</pub-id>
<pub-id pub-id-type="pmid">12099954</pub-id></element-citation></ref><ref id="CIT0022"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muniyappa</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Quon</surname><given-names>MJ</given-names></name></person-group>
<article-title>Current approaches for assessing insulin sensitivity and resistance <italic>in vivo</italic>: Advantages, limitations, and appropriate usage</article-title>
<source><italic>Am J Physiol Endocrinol Metab</italic></source>
<year>2008</year>
<volume>294</volume>
<fpage>E15</fpage>
<lpage>E26</lpage>
<pub-id pub-id-type="pmid">17957034</pub-id></element-citation></ref><ref id="CIT0023"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noor</surname><given-names>MA</given-names></name><name><surname>Parker</surname><given-names>RA</given-names></name><name><surname>O&#x02019;Mara</surname><given-names>E</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults</article-title>
<source><italic>AIDS</italic></source>
<year>2004</year>
<volume>18</volume>
<fpage>2137</fpage>
<lpage>2144</lpage>
<pub-id pub-id-type="doi">10.1097/00002030-200411050-00005</pub-id>
<pub-id pub-id-type="pmid">15577646</pub-id></element-citation></ref><ref id="CIT0024"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noor</surname><given-names>MA</given-names></name><name><surname>Seneviratne</surname><given-names>T</given-names></name><name><surname>Aweeka</surname><given-names>FT</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study</article-title>
<source><italic>AIDS</italic></source>
<year>2002</year>
<volume>16</volume>
<fpage>F1</fpage>
<lpage>F8</lpage>
<pub-id pub-id-type="doi">10.1097/00002030-200203290-00002</pub-id>
<pub-id pub-id-type="pmid">11964551</pub-id></element-citation></ref><ref id="CIT0025"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dub&#x000e9;</surname><given-names>MP</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Greenwald</surname><given-names>M</given-names></name><name><surname>Mather</surname><given-names>KJ</given-names></name></person-group>
<article-title>No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir&#x02010;ritonavir in healthy subjects without HIV infection: A placebo&#x02010;controlled trial</article-title>
<source><italic>Clin Infect Dis</italic></source>
<year>2008</year>
<volume>47</volume>
<fpage>567</fpage>
<lpage>574</lpage>
<pub-id pub-id-type="doi">10.1086/591953</pub-id>
<pub-id pub-id-type="pmid">18636958</pub-id></element-citation></ref><ref id="CIT0026"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>GA</given-names></name><name><surname>Seneviratne</surname><given-names>T</given-names></name><name><surname>Noor</surname><given-names>MA</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>The metabolic effects of lopinavir/ritonavir in HIV-negative men</article-title>
<source><italic>AIDS</italic></source>
<year>2004</year>
<volume>18</volume>
<fpage>641</fpage>
<lpage>649</lpage>
<pub-id pub-id-type="doi">10.1097/00002030-200403050-00008</pub-id>
<pub-id pub-id-type="pmid">15090769</pub-id></element-citation></ref><ref id="CIT0027"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Busti</surname><given-names>AJ</given-names></name><name><surname>Bedimo</surname><given-names>R</given-names></name><name><surname>Margolis</surname><given-names>DM</given-names></name><name><surname>Hardin</surname><given-names>DS</given-names></name></person-group>
<article-title>Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir</article-title>
<source><italic>J Investig Med</italic></source>
<year>2008</year>
<volume>56</volume>
<fpage>539</fpage>
<lpage>544</lpage>
</element-citation></ref><ref id="CIT0028"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Randell</surname><given-names>PA</given-names></name><name><surname>Jackson</surname><given-names>AG</given-names></name><name><surname>Boffito</surname><given-names>M</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men</article-title>
<source><italic>Antivir Ther</italic></source>
<year>2010</year>
<volume>15</volume>
<fpage>1125</fpage>
<lpage>1132</lpage>
<pub-id pub-id-type="doi">10.3851/IMP1675</pub-id>
<pub-id pub-id-type="pmid">21149919</pub-id></element-citation></ref><ref id="CIT0029"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bl&#x000fc;mer</surname><given-names>RM</given-names></name><name><surname>van Vonderen</surname><given-names>MG</given-names></name><name><surname>Sutinen</surname><given-names>J</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Zidovudine/lamivudine contributes to insulin resistance within 3&#x000a0;months of starting combination antiretroviral therapy</article-title>
<source><italic>AIDS</italic></source>
<year>2008</year>
<volume>22</volume>
<fpage>227</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.1097/QAD.0b013e3282f33557</pub-id>
<pub-id pub-id-type="pmid">18097225</pub-id></element-citation></ref><ref id="CIT0030"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Defronzo</surname><given-names>RA</given-names></name><name><surname>Tobin</surname><given-names>JD</given-names></name><name><surname>Andres</surname><given-names>R</given-names></name></person-group>
<article-title>Glucose clamp technique: A method for quantifying insulin secretion and resistance</article-title>
<source><italic>Am J Physiol</italic></source>
<year>1979</year>
<volume>237</volume>
<fpage>E214</fpage>
<lpage>E223</lpage>
<pub-id pub-id-type="pmid">382871</pub-id></element-citation></ref><ref id="CIT0031"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Molina</surname><given-names>JM</given-names></name><name><surname>Andrade-Villanueva</surname><given-names>J</given-names></name><name><surname>Echevarria</surname><given-names>J</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48&#x000a0;week efficacy and safety results of the CASTLE study</article-title>
<source><italic>Lancet</italic></source>
<year>2008</year>
<volume>372</volume>
<fpage>646</fpage>
<lpage>655</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(08)61081-8</pub-id>
<pub-id pub-id-type="pmid">18722869</pub-id></element-citation></ref><ref id="CIT0032"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bergman</surname><given-names>RN</given-names></name><name><surname>Finegood</surname><given-names>DT</given-names></name><name><surname>Ader</surname><given-names>M</given-names></name></person-group>
<article-title>Assessment of insulin sensitivity in vivo</article-title>
<source><italic>Endocr Rev</italic></source>
<year>1985</year>
<volume>6</volume>
<fpage>45</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1210/edrv-6-1-45</pub-id>
<pub-id pub-id-type="pmid">3884329</pub-id></element-citation></ref><ref id="CIT0033"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tomaka</surname><given-names>F</given-names></name><name><surname>Lefebvre</surname><given-names>E</given-names></name><name><surname>Sekar</surname><given-names>V</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers</article-title>
<source><italic>HIV Med</italic></source>
<year>2009</year>
<volume>10</volume>
<fpage>318</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="doi">10.1111/hiv.2009.10.issue-5</pub-id>
<pub-id pub-id-type="pmid">19210693</pub-id></element-citation></ref></ref-list></back></article>